Genelux Corporation (NASDAQ: GNLX), a late clinical-stage biotechnology company, has secured $20.0 million in funding from investors. This capital infusion is intended to advance the company's mission of improving the lives of patients affected by difficult-to-treat solid tumors through its innovative oncolytic immunotherapy approach. Genelux is known for its ChoiceTM Discovery Platform, which has generated numerous versions of the vaccinia virus for therapeutic development.
The company's lead product candidate, Olvi-Vec, is currently undergoing a Phase 3 registrational clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Olvi-Vec is also being developed for other challenging indications, including Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer. This funding round underscores continued investor confidence in Genelux's clinical pipeline and its potential to address significant unmet medical needs in oncology.
Genelux plans to allocate the newly raised capital towards supporting the ongoing clinical development of Olvi-Vec and advancing its pipeline of next-generation oncolytic immunotherapies. These therapies are designed to deliver a full complement of tumor neo-antigens, aiming to stimulate a personalized immune response in patients suffering from aggressive and/or difficult-to-treat solid tumor types. The investment will facilitate the company's efforts to bring these investigational treatments closer to patients.
This funding is expected to bolster Genelux's operational capabilities and accelerate its strategic growth initiatives. The company remains dedicated to its goal of developing novel therapeutic options that can make a meaningful difference for cancer patients, continuing its work to expand the potential applications of its oncolytic immunotherapy platform.
.png&w=3840&q=75)
